We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Proteins Identified Block Growth of KRAS-Mutant Cancers

By LabMedica International staff writers
Posted on 18 Oct 2016
Print article
Image: A mouse model was used to show that microRNA miR-1298 specifically killed cancer cells with a common mutation in the KRAS gene (Photo courtesy of University of California, San Diego).
Image: A mouse model was used to show that microRNA miR-1298 specifically killed cancer cells with a common mutation in the KRAS gene (Photo courtesy of University of California, San Diego).
A team of cancer researchers has defined a novel regulatory pathway in KRAS-driven cancers, which offers a potential therapeutic target for their eradication.

Approximately 20% of all human cancers have mutations in the KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) gene. These KRAS-mutant cancers are among the most difficult to treat due to their resistance to chemotherapy.

Investigators at the University of California San Diego (USA) used microRNA (miRNA) functional screens to identify synthetic lethal interactions in KRAS-mutant cancer cells that showed potential be exploited therapeutically.

MiRNAs are a small noncoding family of 19- to 25-nucleotide RNAs that regulate gene expression by targeting messenger RNAs (mRNAs) in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.

The investigators reported in the October 1, 2016, online edition of the journal Cancer Research that they identified the microRNA miR-1298 in a screen that distinguished between miRNAs that blocked the growth of colorectal and lung cancer cells with mutated KRAS but failed to block the growth of the same types of cancer with normal KRAS. Using affinity purification technology, they identified the proteins tyrosine kinase FAK (Focal adhesion kinase) and the laminin subunit LAMB3 (Laminin subunit beta-3) as functional targets of miR-1298.

Further experiments showed that silencing of FAK or LAMB3 inhibited the growth of mutant KRAS-driven cancer cells, in the same manner as miR-1298. Expression of LAMB3 but not FAK was upregulated by mutant KRAS. In clinical specimens, elevated LAMB3 expression correlated with poorer survival in lung cancer patients with an oncogenic KRAS gene signature, suggesting that it might be a novel candidate biomarker in this disease setting.

“For decades researchers have tried to directly inhibit KRAS activity, but there are no well-defined binding pockets in the protein that we can target with small-molecule drugs,” said senior author Dr. Tariq Rana, professor of pediatrics at the University of California, San Diego. “Instead of trying to deter KRAS itself, we took the approach of looking for other molecules that, when inhibited, are lethal to cells only when KRAS is also mutated.”

“This clinical finding suggests LAMB3 could be used as a prognostic biomarker, and underscores LAMB3’s potential as a therapeutic target for KRAS-driven cancers,” said Dr. Rana. “What is more, it highlights miRNAs as important tools for probing complex biological processes, identifying new therapeutic targets and developing potential new RNA-based therapeutics.”

Related Links:
University of California San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.